Greg Tiao, MD
Disclosures: Nothing to disclose

Greg M. Tiao, M.D.

Professor of Surgery and Pediatrics

Division Director, Pediatric Surgery

Surgical Director, Transplantation

Frederick C. Ryckman Chair in Pediatric Surgery

Cincinnati Children’s Hospital Medical Center



As a pediatric and abdominal transplant surgeon, I am involved in all aspects of the care of children afflicted with primary hepatic malignancies including hepatoblastoma, hepatocellular carcinoma, and uncommon lesions such as; undifferentiated embryonal sarcomas, rhabdoid tumors of the liver, and hemangiosarcomas. As my experience grew, I was able to join the Children’s Oncology Group rare tumor liver subcommittee in 2009. I am fortunate to contribute to the team and was given the responsibility of developing (in collaboration with investigators from around the world) the next COG supported liver tumor treatment trial to be conducted as an international study. The proposal will be submitted for scientific review soon.

Defining the pathogenesis of these tumors such that therapeutic strategies can be developed eliminating complex surgical interventions is a logical extension of my career goals. My NIH supported independent research laboratory investigates the pathogenesis of virus induced biliary atresia specifically seeking to determine the mechanistic basis of this disease so that new treatment strategies can be developed to salvage the native liver. From that perspective, I have established a research approach in which a clinically significant disease process is studied mechanistically with the goal of translating bench findings to patient care. This approach fits well with the evolving clinical and research program we have established at CCHMC focused on pediatric liver tumors.

I have work effectively with other co-investigators in the Cincinnati Cancer Blood Disease Institute and the Liver Care Center (Geller, Timchenko, Bezerra) to provide comprehensive evaluation for children with primary tumors of the liver. Dr. Timchenko’s R01 application investigates mechanisms of hepatoblastoma and proposes generation and analysis of patient derived xenografts.  I am happy to collaborate with Dr. Timchenko in investigation of mechanistic pathways in pediatric liver tumorigenesis and I will provide high quality well annotated patient based specimens. In collaborations with Dr. Bondoc (outstanding surgeon and scientist), we will establish PDXs of classic and aggressive HBL for the studies proposed in Specific Aim 3 of Dr. Timchenko’a application. This will allow translation of mechanistic studies established in murine models to be studied in human tissue. We are working together with Dr. Timchenko for over 3 years and we have recently published our fundamental observations showing mechanisms of classic hepatoblastoma (Valanejad et al. Carcinogenesis 2017, see ref #4 below). I will continue this collaboration taking advantage of the rich tissue and data that our institution has gathered to understand clinical, pathological, and cellular drivers of clinical outcome.